Biocon secures USFDA approval for generic Liraglutide, entering the lucrative US obesity treatment market with gSaxenda.

Biocon Ltd is quoting at Rs 394.6, up 0.99% on the day as on 12:44 IST on the NSE. The stock is up 26.54% in last one year as compared to a 13.13% jump in NIFTY and a 13.84% jump in the Nifty Pharma.

Biocon Limited ( (IN:BIOCON)) just unveiled an update. Biocon Limited has increased its ownership in its unlisted material subsidiary, Biocon Biologics Limited (BBL), to around 94% of BBL’s fully ...

Biotech firm Biocon on Thursday said it has raised ₹4,150 crore through a Qualified Institutions Placement (QIP) process. The ...

Nuvama has flagged four pharma stocks as top ‘Buy’ picks, citing strong US launches, biosimilars traction and margin ...

On Friday, market tech analysts Somil Mehta, Shrikant Chouhan and Mitessh Thakkar recommended these stocks for the short term.

Biocon posts 9% rise in Q3FY26 revenue to Rs 4,173 crore; net profit jumps to Rs 143.8 crore on strong generics and ...

Zee Business analysts have shared a number of short- and long-term calls, including Tata Motors PV, Infosys, Dr Reddy’s, RVNL ...

LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, ...

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S's Ozempic and Wegovy in key markets as patents on the blockbuster weight-loss drugs expire next year. The ...